BR112018069930B1 - Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica - Google Patents

Info

Publication number

BR112018069930B1

BR112018069930B1 BR112018069930-6A BR112018069930A BR112018069930B1 BR 112018069930 B1 BR112018069930 B1 BR 112018069930B1 BR 112018069930 A BR112018069930 A BR 112018069930A BR 112018069930 B1 BR112018069930 B1 BR 112018069930B1

Authority

BR

Brazil

Prior art keywords

disease

compound

trifluoromethyl

pharmaceutically acceptable

methyl

Prior art date

2016-04-13

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 216
• 239000008194 pharmaceutical composition Substances 0.000 title claims description 13
• 239000000556 agonist Substances 0.000 title description 8
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title description 7
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 67
• 108010015181 PPAR delta Proteins 0.000 claims abstract description 51
• 201000010099 disease Diseases 0.000 claims abstract description 41
• 208000030159 metabolic disease Diseases 0.000 claims abstract description 11
• 208000019553 vascular disease Diseases 0.000 claims abstract description 8
• 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 6
• 208000021642 Muscular disease Diseases 0.000 claims abstract description 6
• 150000003839 salts Chemical class 0.000 claims description 45
• -1 halomethoxy Chemical group 0.000 claims description 29
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 23
• 208000035475 disorder Diseases 0.000 claims description 21
• 229910052736 halogen Inorganic materials 0.000 claims description 19
• 150000002367 halogens Chemical group 0.000 claims description 19
• 229910052739 hydrogen Inorganic materials 0.000 claims description 13
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
• 239000001257 hydrogen Substances 0.000 claims description 11
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
• 210000003205 muscle Anatomy 0.000 claims description 10
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 9
• 239000003814 drug Substances 0.000 claims description 9
• 125000002541 furyl group Chemical group 0.000 claims description 9
• 201000006938 muscular dystrophy Diseases 0.000 claims description 9
• 208000011580 syndromic disease Diseases 0.000 claims description 9
• 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims description 8
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
• 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 7
• 230000002093 peripheral effect Effects 0.000 claims description 7
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 6
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 6
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 6
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
• 208000004350 Strabismus Diseases 0.000 claims description 6
• 229910052801 chlorine Inorganic materials 0.000 claims description 6
• 208000002780 macular degeneration Diseases 0.000 claims description 6
• 208000012268 mitochondrial disease Diseases 0.000 claims description 6
• 238000007254 oxidation reaction Methods 0.000 claims description 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
• 206010020772 Hypertension Diseases 0.000 claims description 5
• 208000035177 MELAS Diseases 0.000 claims description 5
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 229910052731 fluorine Inorganic materials 0.000 claims description 5
• 201000006417 multiple sclerosis Diseases 0.000 claims description 5
• 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 claims description 4
• 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 claims description 4
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 4
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
• 206010022562 Intermittent claudication Diseases 0.000 claims description 4
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
• 208000035172 MERRF Diseases 0.000 claims description 4
• 208000029578 Muscle disease Diseases 0.000 claims description 4
• 206010049565 Muscle fatigue Diseases 0.000 claims description 4
• 201000009623 Myopathy Diseases 0.000 claims description 4
• 208000014245 Ocular vascular disease Diseases 0.000 claims description 4
• 208000013234 Pearson syndrome Diseases 0.000 claims description 4
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
• 230000007812 deficiency Effects 0.000 claims description 4
• 206010012601 diabetes mellitus Diseases 0.000 claims description 4
• 208000016097 disease of metabolism Diseases 0.000 claims description 4
• 125000004970 halomethyl group Chemical group 0.000 claims description 4
• 208000006750 hematuria Diseases 0.000 claims description 4
• 208000021156 intermittent vascular claudication Diseases 0.000 claims description 4
• 208000017169 kidney disease Diseases 0.000 claims description 4
• 208000036546 leukodystrophy Diseases 0.000 claims description 4
• 201000008383 nephritis Diseases 0.000 claims description 4
• 230000008555 neuronal activation Effects 0.000 claims description 4
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
• 208000030613 peripheral artery disease Diseases 0.000 claims description 4
• 238000002360 preparation method Methods 0.000 claims description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
• 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 4
• YBDMLCZZFCXIHA-MRXNPFEDSA-N (3R)-6-[2-[[5-chloro-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]-3-methylhexanoic acid Chemical group ClC1=CN=C(N1CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)C1=CC=C(C=C1)C(F)(F)F YBDMLCZZFCXIHA-MRXNPFEDSA-N 0.000 claims description 3
• 206010003591 Ataxia Diseases 0.000 claims description 3
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 3
• 206010019280 Heart failures Diseases 0.000 claims description 3
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
• 201000009035 MERRF syndrome Diseases 0.000 claims description 3
• 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 3
• 208000010428 Muscle Weakness Diseases 0.000 claims description 3
• 206010028372 Muscular weakness Diseases 0.000 claims description 3
• 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 claims description 3
• 208000008589 Obesity Diseases 0.000 claims description 3
• 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 3
• 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims description 3
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
• 208000032978 Structural Congenital Myopathies Diseases 0.000 claims description 3
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
• 201000009338 distal myopathy Diseases 0.000 claims description 3
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 3
• 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 3
• 208000006443 lactic acidosis Diseases 0.000 claims description 3
• 201000000585 muscular atrophy Diseases 0.000 claims description 3
• 230000001272 neurogenic effect Effects 0.000 claims description 3
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
• 235000020824 obesity Nutrition 0.000 claims description 3
• 206010030875 ophthalmoplegia Diseases 0.000 claims description 3
• 230000003647 oxidation Effects 0.000 claims description 3
• 210000001696 pelvic girdle Anatomy 0.000 claims description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
• FIJLCEFJEJQDGD-MRXNPFEDSA-N (3R)-6-[2-[[2-(4-chlorophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoic acid Chemical group ClC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 FIJLCEFJEJQDGD-MRXNPFEDSA-N 0.000 claims description 2
• DXLKPRPZCXLXEJ-QGZVFWFLSA-N (3R)-6-[2-[[2-(4-cyanophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoic acid Chemical group C(#N)C1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 DXLKPRPZCXLXEJ-QGZVFWFLSA-N 0.000 claims description 2
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
• 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
• 208000036022 Alpers' disease Diseases 0.000 claims description 2
• 208000024827 Alzheimer disease Diseases 0.000 claims description 2
• 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 2
• 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 2
• 201000001320 Atherosclerosis Diseases 0.000 claims description 2
• 208000012904 Bartter disease Diseases 0.000 claims description 2
• 208000010062 Bartter syndrome Diseases 0.000 claims description 2
• 208000006304 Bethlem myopathy Diseases 0.000 claims description 2
• 206010006895 Cachexia Diseases 0.000 claims description 2
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
• 101710147349 Carnitine transporter Proteins 0.000 claims description 2
• 208000015374 Central core disease Diseases 0.000 claims description 2
• 201000003728 Centronuclear myopathy Diseases 0.000 claims description 2
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
• 208000035902 Critical illness myopathy Diseases 0.000 claims description 2
• 208000011231 Crohn disease Diseases 0.000 claims description 2
• AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
• 201000004624 Dermatitis Diseases 0.000 claims description 2
• 208000002249 Diabetes Complications Diseases 0.000 claims description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
• 206010012655 Diabetic complications Diseases 0.000 claims description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 102000004190 Enzymes Human genes 0.000 claims description 2
• 108090000790 Enzymes Proteins 0.000 claims description 2
• 208000001692 Esotropia Diseases 0.000 claims description 2
• 201000005538 Exotropia Diseases 0.000 claims description 2
• 208000001640 Fibromyalgia Diseases 0.000 claims description 2
• 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
• 208000010412 Glaucoma Diseases 0.000 claims description 2
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
• 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 2
• 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
• 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 2
• 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
• 206010020675 Hypermetropia Diseases 0.000 claims description 2
• 206010020740 Hyperproteinaemia Diseases 0.000 claims description 2
• 206010020751 Hypersensitivity Diseases 0.000 claims description 2
• 206010020961 Hypocholesterolaemia Diseases 0.000 claims description 2
• 208000034767 Hypoproteinaemia Diseases 0.000 claims description 2
• 206010061218 Inflammation Diseases 0.000 claims description 2
• 206010022489 Insulin Resistance Diseases 0.000 claims description 2
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 2
• 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims description 2
• 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims description 2
• 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
• 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 2
• 206010028289 Muscle atrophy Diseases 0.000 claims description 2
• 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
• 208000034965 Nemaline Myopathies Diseases 0.000 claims description 2
• 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
• 206010029323 Neuromyopathy Diseases 0.000 claims description 2
• 208000004286 Osteochondrodysplasias Diseases 0.000 claims description 2
• 206010033645 Pancreatitis Diseases 0.000 claims description 2
• 206010036802 Progressive external ophthalmoplegia Diseases 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 208000033626 Renal failure acute Diseases 0.000 claims description 2
• 208000037111 Retinal Hemorrhage Diseases 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
• 208000018675 Schwartz-Jampel syndrome Diseases 0.000 claims description 2
• 201000003222 Schwartz-Jampel syndrome 1 Diseases 0.000 claims description 2
• 108010052164 Sodium Channels Proteins 0.000 claims description 2
• 102000018674 Sodium Channels Human genes 0.000 claims description 2
• 208000027073 Stargardt disease Diseases 0.000 claims description 2
• 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
• 208000007536 Thrombosis Diseases 0.000 claims description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
• 206010054880 Vascular insufficiency Diseases 0.000 claims description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
• 230000004308 accommodation Effects 0.000 claims description 2
• 206010000496 acne Diseases 0.000 claims description 2
• 201000011040 acute kidney failure Diseases 0.000 claims description 2
• 208000012998 acute renal failure Diseases 0.000 claims description 2
• 230000001919 adrenal effect Effects 0.000 claims description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
• 206010002537 anisometropia Diseases 0.000 claims description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
• 210000001367 artery Anatomy 0.000 claims description 2
• 206010003246 arthritis Diseases 0.000 claims description 2
• 208000006673 asthma Diseases 0.000 claims description 2
• 201000009310 astigmatism Diseases 0.000 claims description 2
• 210000000481 breast Anatomy 0.000 claims description 2
• 210000000845 cartilage Anatomy 0.000 claims description 2
• 201000007303 central core myopathy Diseases 0.000 claims description 2
• 206010008129 cerebral palsy Diseases 0.000 claims description 2
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
• 208000020832 chronic kidney disease Diseases 0.000 claims description 2
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
• 206010010121 compartment syndrome Diseases 0.000 claims description 2
• 230000007850 degeneration Effects 0.000 claims description 2
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
• 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
• 208000007345 glycogen storage disease Diseases 0.000 claims description 2
• 201000004502 glycogen storage disease II Diseases 0.000 claims description 2
• 208000014391 hyaline body myopathy Diseases 0.000 claims description 2
• 201000001421 hyperglycemia Diseases 0.000 claims description 2
• 201000008980 hyperinsulinism Diseases 0.000 claims description 2
• 201000006318 hyperopia Diseases 0.000 claims description 2
• 230000004305 hyperopia Effects 0.000 claims description 2
• 230000001631 hypertensive effect Effects 0.000 claims description 2
• 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
• 201000008319 inclusion body myositis Diseases 0.000 claims description 2
• 230000004054 inflammatory process Effects 0.000 claims description 2
• 210000002429 large intestine Anatomy 0.000 claims description 2
• 210000004072 lung Anatomy 0.000 claims description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
• 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 2
• 230000020763 muscle atrophy Effects 0.000 claims description 2
• 230000003387 muscular Effects 0.000 claims description 2
• 208000029372 muscular lipidosis Diseases 0.000 claims description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
• 206010028417 myasthenia gravis Diseases 0.000 claims description 2
• 208000001491 myopia Diseases 0.000 claims description 2
• 230000004379 myopia Effects 0.000 claims description 2
• 201000009925 nephrosclerosis Diseases 0.000 claims description 2
• 230000004770 neurodegeneration Effects 0.000 claims description 2
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
• 210000001672 ovary Anatomy 0.000 claims description 2
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
• 230000002085 persistent effect Effects 0.000 claims description 2
• 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
• 201000010041 presbyopia Diseases 0.000 claims description 2
• 230000000750 progressive effect Effects 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims description 2
• 230000000306 recurrent effect Effects 0.000 claims description 2
• 235000019192 riboflavin Nutrition 0.000 claims description 2
• 239000002151 riboflavin Substances 0.000 claims description 2
• 229960002477 riboflavin Drugs 0.000 claims description 2
• 208000001076 sarcopenia Diseases 0.000 claims description 2
• 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims description 2
• 210000003491 skin Anatomy 0.000 claims description 2
• 230000009759 skin aging Effects 0.000 claims description 2
• 230000009885 systemic effect Effects 0.000 claims description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
• 231100000399 thyrotoxic Toxicity 0.000 claims description 2
• 230000001897 thyrotoxic effect Effects 0.000 claims description 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
• 208000023577 vascular insufficiency disease Diseases 0.000 claims description 2
• YSSLMLSKYLOHJM-MRXNPFEDSA-N (3R)-3-methyl-6-[2-[[5-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoic acid Chemical group C[C@H](CCCOc1ccccc1Cn1c(cnc1-c1ccc(cc1)C(F)(F)F)C(F)(F)F)CC(O)=O YSSLMLSKYLOHJM-MRXNPFEDSA-N 0.000 claims 1
• 206010006187 Breast cancer Diseases 0.000 claims 1
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• 206010009944 Colon cancer Diseases 0.000 claims 1
• 208000017870 Congenital fiber-type disproportion myopathy Diseases 0.000 claims 1
• 102100034239 Emerin Human genes 0.000 claims 1
• 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 claims 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 206010033799 Paralysis Diseases 0.000 claims 1
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
• 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
• 208000000453 Skin Neoplasms Diseases 0.000 claims 1
• 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
• 210000000748 cardiovascular system Anatomy 0.000 claims 1
• 208000029742 colonic neoplasm Diseases 0.000 claims 1
• 201000011477 congenital fiber-type disproportion Diseases 0.000 claims 1
• 208000011069 eye accommodation disease Diseases 0.000 claims 1
• 150000002431 hydrogen Chemical group 0.000 claims 1
• 201000005202 lung cancer Diseases 0.000 claims 1
• 201000005296 lung carcinoma Diseases 0.000 claims 1
• 208000020816 lung neoplasm Diseases 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 210000005036 nerve Anatomy 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 208000021090 palsy Diseases 0.000 claims 1
• 201000001514 prostate carcinoma Diseases 0.000 claims 1
• 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 40
• 230000000694 effects Effects 0.000 abstract description 16
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
• 230000015572 biosynthetic process Effects 0.000 description 91
• 238000003786 synthesis reaction Methods 0.000 description 90
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 82
• 239000011541 reaction mixture Substances 0.000 description 70
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 62
• 239000000243 solution Substances 0.000 description 57
• 238000005160 1H NMR spectroscopy Methods 0.000 description 53
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 50
• 235000019439 ethyl acetate Nutrition 0.000 description 44
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
• 238000006243 chemical reaction Methods 0.000 description 42
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 42
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 40
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
• 238000002474 experimental method Methods 0.000 description 38
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
• 235000002639 sodium chloride Nutrition 0.000 description 34
• 239000002585 base Substances 0.000 description 33
• 239000012299 nitrogen atmosphere Substances 0.000 description 31
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
• 239000007832 Na2SO4 Substances 0.000 description 30
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
• 229910052938 sodium sulfate Inorganic materials 0.000 description 30
• 235000011152 sodium sulphate Nutrition 0.000 description 30
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 28
• 239000000284 extract Substances 0.000 description 26
• 239000012267 brine Substances 0.000 description 25
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
• OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 24
• 238000004293 19F NMR spectroscopy Methods 0.000 description 22
• 235000015320 potassium carbonate Nutrition 0.000 description 21
• 229910000027 potassium carbonate Inorganic materials 0.000 description 21
• 239000007787 solid Substances 0.000 description 21
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
• 238000000034 method Methods 0.000 description 18
• 239000002253 acid Substances 0.000 description 17
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
• 238000010828 elution Methods 0.000 description 16
• 238000010898 silica gel chromatography Methods 0.000 description 16
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 15
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• KEQLCUZKLBSQTD-MRVPVSSYSA-N ethyl (3R)-6-bromo-3-methylhexanoate Chemical compound BrCCC[C@H](CC(=O)OCC)C KEQLCUZKLBSQTD-MRVPVSSYSA-N 0.000 description 15
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
• 229910015845 BBr3 Inorganic materials 0.000 description 14
• 238000004128 high performance liquid chromatography Methods 0.000 description 12
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 12
• 210000004027 cell Anatomy 0.000 description 11
• 239000003153 chemical reaction reagent Substances 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 238000011282 treatment Methods 0.000 description 11
• 125000000217 alkyl group Chemical group 0.000 description 10
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
• 125000003118 aryl group Chemical group 0.000 description 8
• WVKIFIROCHIWAY-UHFFFAOYSA-N hydron;2-(methylamino)acetic acid;chloride Chemical compound Cl.CNCC(O)=O WVKIFIROCHIWAY-UHFFFAOYSA-N 0.000 description 8
• MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 8
• PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 7
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 7
• 238000001228 spectrum Methods 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 6
• 239000007789 gas Substances 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 239000002994 raw material Substances 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• WAUNFWSVXRPCDQ-UHFFFAOYSA-N 1-(bromomethyl)-2-methoxybenzene Chemical compound COC1=CC=CC=C1CBr WAUNFWSVXRPCDQ-UHFFFAOYSA-N 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
• 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 5
• 239000012300 argon atmosphere Substances 0.000 description 5
• WIKQEUJFZPCFNJ-UHFFFAOYSA-N carbonic acid;silver Chemical compound [Ag].[Ag].OC(O)=O WIKQEUJFZPCFNJ-UHFFFAOYSA-N 0.000 description 5
• 239000000460 chlorine Substances 0.000 description 5
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 108020001756 ligand binding domains Proteins 0.000 description 5
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 5
• 230000007935 neutral effect Effects 0.000 description 5
• 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 5
• LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 5
• KQTXIZHBFFWWFW-UHFFFAOYSA-L silver(I) carbonate Inorganic materials [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 229910052786 argon Inorganic materials 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• SSJQOTXWMLWHOK-MRVPVSSYSA-N ethyl (3R)-6-hydroxy-3-methylhexanoate Chemical compound OCCC[C@H](CC(=O)OCC)C SSJQOTXWMLWHOK-MRVPVSSYSA-N 0.000 description 4
• PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 4
• 125000000623 heterocyclic group Chemical group 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• 229910052740 iodine Inorganic materials 0.000 description 4
• 239000011630 iodine Substances 0.000 description 4
• 125000002950 monocyclic group Chemical group 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
• 239000012085 test solution Substances 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
• RCHMZPOLZQAVSX-UHFFFAOYSA-N 5-iodo-1-[(2-methoxyphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]imidazole Chemical compound IC1=CN=C(N1CC1=C(C=CC=C1)OC)C1=CC=C(C=C1)C(F)(F)F RCHMZPOLZQAVSX-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• LUGFXTJIJHEVSS-UHFFFAOYSA-N C(C)(=O)OIOC(C)=O Chemical compound C(C)(=O)OIOC(C)=O LUGFXTJIJHEVSS-UHFFFAOYSA-N 0.000 description 3
• PHFHDUSAONDBHH-UHFFFAOYSA-N COC1=C(CN2C=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 PHFHDUSAONDBHH-UHFFFAOYSA-N 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 3
• 241000700157 Rattus norvegicus Species 0.000 description 3
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
• 125000003545 alkoxy group Chemical group 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 235000019441 ethanol Nutrition 0.000 description 3
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 239000011737 fluorine Substances 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 235000017557 sodium bicarbonate Nutrition 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 235000017550 sodium carbonate Nutrition 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• ZTPXUNKAKRPJQL-MRXNPFEDSA-N (3R)-6-[2-[[2-(4-fluorophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoic acid Chemical compound C[C@H](CCCOc1ccccc1Cn1c(cnc1-c1ccc(F)cc1)C(F)(F)F)CC(O)=O ZTPXUNKAKRPJQL-MRXNPFEDSA-N 0.000 description 2
• GJWSUKYXUMVMGX-SECBINFHSA-N (R)-citronellic acid Chemical compound OC(=O)C[C@H](C)CCC=C(C)C GJWSUKYXUMVMGX-SECBINFHSA-N 0.000 description 2
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
• SUDDUNKTTRAAJP-UHFFFAOYSA-N 1-[(2-methoxyphenyl)methyl]-2-[4-(trifluoromethoxy)phenyl]-5-(trifluoromethyl)imidazole Chemical compound COC1=C(CN2C(=CN=C2C2=CC=C(OC(F)(F)F)C=C2)C(F)(F)F)C=CC=C1 SUDDUNKTTRAAJP-UHFFFAOYSA-N 0.000 description 2
• GOLQPDPKNJQJTB-UHFFFAOYSA-N 1-[(2-methoxyphenyl)methyl]-5-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]imidazole Chemical compound COC1=C(CN2C(=CN=C2C2=CC=C(C=C2)C(F)(F)F)C(F)(F)F)C=CC=C1 GOLQPDPKNJQJTB-UHFFFAOYSA-N 0.000 description 2
• QIXRTRCPPVFZGV-UHFFFAOYSA-N 2-(4-bromophenyl)-1-[(2-methoxyphenyl)methyl]-5-(trifluoromethyl)imidazole Chemical compound BrC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)OC QIXRTRCPPVFZGV-UHFFFAOYSA-N 0.000 description 2
• HOMORCNPZBHTAK-UHFFFAOYSA-N 2-(4-bromophenyl)-1-[(2-methoxyphenyl)methyl]imidazole Chemical compound COC1=CC=CC=C1CN1C(C=2C=CC(Br)=CC=2)=NC=C1 HOMORCNPZBHTAK-UHFFFAOYSA-N 0.000 description 2
• IRIGPPDONXVEHU-UHFFFAOYSA-N 2-(4-bromophenyl)-1h-imidazole Chemical compound C1=CC(Br)=CC=C1C1=NC=CN1 IRIGPPDONXVEHU-UHFFFAOYSA-N 0.000 description 2
• UMIZQBIGMUWVTO-UHFFFAOYSA-N 2-(4-bromophenyl)-4,5-dihydro-1h-imidazole Chemical compound C1=CC(Br)=CC=C1C1=NCCN1 UMIZQBIGMUWVTO-UHFFFAOYSA-N 0.000 description 2
• IEFQPHCLTIFJIH-UHFFFAOYSA-N 2-(4-bromophenyl)-5-iodo-1-[(2-methoxyphenyl)methyl]imidazole Chemical compound BrC1=CC=C(C=C1)C=1N(C(=CN=1)I)CC1=C(C=CC=C1)OC IEFQPHCLTIFJIH-UHFFFAOYSA-N 0.000 description 2
• GDGQJMXISQYWRF-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-[(2-methoxyphenyl)methyl]-5-(trifluoromethyl)imidazole Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)OC GDGQJMXISQYWRF-UHFFFAOYSA-N 0.000 description 2
• PNAXDBRFHLLGFD-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-(2,2,2-trifluoroacetyl)-4H-1,3-oxazol-5-one Chemical compound ClC1=CC=C(C=C1)C=1OC(C(N=1)C(C(F)(F)F)=O)=O PNAXDBRFHLLGFD-UHFFFAOYSA-N 0.000 description 2
• BEWGWLFEIWPMRS-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[(2-methoxyphenyl)methyl]-5-(trifluoromethyl)imidazole Chemical compound FC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)OC BEWGWLFEIWPMRS-UHFFFAOYSA-N 0.000 description 2
• ZRZDTFSTXRNKAY-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(2,2,2-trifluoroacetyl)-4H-1,3-oxazol-5-one Chemical compound FC1=CC=C(C=C1)C=1OC(C(N=1)C(C(F)(F)F)=O)=O ZRZDTFSTXRNKAY-UHFFFAOYSA-N 0.000 description 2
• PILWEIKZLBUAHE-UHFFFAOYSA-N 2-(4-iodophenyl)-1-[(2-methoxyphenyl)methyl]-5-(trifluoromethyl)imidazole Chemical compound IC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)OC PILWEIKZLBUAHE-UHFFFAOYSA-N 0.000 description 2
• OTOWZJSXOWJMFA-UHFFFAOYSA-N 2-(4-iodophenyl)-4-(2,2,2-trifluoroacetyl)-4H-1,3-oxazol-5-one Chemical compound IC1=CC=C(C=C1)C=1OC(C(N=1)C(C(F)(F)F)=O)=O OTOWZJSXOWJMFA-UHFFFAOYSA-N 0.000 description 2
• COYZIYOEXGRBHQ-UHFFFAOYSA-N 2-[(4-chlorobenzoyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)C1=CC=C(Cl)C=C1 COYZIYOEXGRBHQ-UHFFFAOYSA-N 0.000 description 2
• DVALMHFCJYLXPH-UHFFFAOYSA-N 2-[(4-iodobenzoyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)C1=CC=C(I)C=C1 DVALMHFCJYLXPH-UHFFFAOYSA-N 0.000 description 2
• SWDKWZQLMUSLRH-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC=CN1 SWDKWZQLMUSLRH-UHFFFAOYSA-N 0.000 description 2
• XYDNTALWFYHWQB-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NCCN1 XYDNTALWFYHWQB-UHFFFAOYSA-N 0.000 description 2
• IAYSSWQLMYANTP-UHFFFAOYSA-N 2-[[2-(4-bromophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenol Chemical compound BrC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)O IAYSSWQLMYANTP-UHFFFAOYSA-N 0.000 description 2
• OEBPZEAMIVXMSH-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenol Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)O OEBPZEAMIVXMSH-UHFFFAOYSA-N 0.000 description 2
• VFGNBNMHYDVEJE-UHFFFAOYSA-N 2-[[2-(4-fluorophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenol Chemical compound FC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)O VFGNBNMHYDVEJE-UHFFFAOYSA-N 0.000 description 2
• HNCALCUJXGDNNX-UHFFFAOYSA-N 2-[[2-(4-iodophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenol Chemical compound IC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)O HNCALCUJXGDNNX-UHFFFAOYSA-N 0.000 description 2
• SHIIFRGDFCNRAS-UHFFFAOYSA-N 2-[[2-[4-(trifluoromethoxy)phenyl]-5-(trifluoromethyl)imidazol-1-yl]methyl]phenol Chemical compound FC(OC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(C=CC=C1)O)(F)F SHIIFRGDFCNRAS-UHFFFAOYSA-N 0.000 description 2
• CFMFZXDMVTUOJV-UHFFFAOYSA-N 2-[[5-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenol Chemical compound FC(C1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C(F)(F)F)(F)F CFMFZXDMVTUOJV-UHFFFAOYSA-N 0.000 description 2
• KGXQOGNXIBRZJZ-UHFFFAOYSA-N 2-[[5-chloro-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenol Chemical compound ClC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C(F)(F)F KGXQOGNXIBRZJZ-UHFFFAOYSA-N 0.000 description 2
• HVAPLSNCVYXFDQ-UHFFFAOYSA-N 3,3-dimethyl-1-(trifluoromethyl)-1$l^{3},2-benziodoxole Chemical compound C1=CC=C2C(C)(C)OI(C(F)(F)F)C2=C1 HVAPLSNCVYXFDQ-UHFFFAOYSA-N 0.000 description 2
• VWBKNBLQKNGMEE-UHFFFAOYSA-N 3-[(2-hydroxyphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]imidazole-4-carbonitrile Chemical compound OC1=C(CN2C(=CN=C2C2=CC=C(C=C2)C(F)(F)F)C#N)C=CC=C1 VWBKNBLQKNGMEE-UHFFFAOYSA-N 0.000 description 2
• JUFYHNFVUAMAEL-UHFFFAOYSA-N 3-[(2-methoxyphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]imidazole-4-carbonitrile Chemical compound COC1=C(CN2C(=CN=C2C2=CC=C(C=C2)C(F)(F)F)C#N)C=CC=C1 JUFYHNFVUAMAEL-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• ISJCKCQDMBPKML-UHFFFAOYSA-N 4-(1h-imidazol-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=NC=CN1 ISJCKCQDMBPKML-UHFFFAOYSA-N 0.000 description 2
• JYRGLBHUUQQUGO-UHFFFAOYSA-N 4-(2,2,2-trifluoroacetyl)-2-[4-(trifluoromethoxy)phenyl]-4H-1,3-oxazol-5-one Chemical compound FC(C(=O)C1N=C(OC1=O)C1=CC=C(C=C1)OC(F)(F)F)(F)F JYRGLBHUUQQUGO-UHFFFAOYSA-N 0.000 description 2
• QSYOBRLVRMIBRU-UHFFFAOYSA-N 4-(4,5-dihydro-1h-imidazol-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1=NCCN1 QSYOBRLVRMIBRU-UHFFFAOYSA-N 0.000 description 2
• NPIUXDQKRHXKGZ-UHFFFAOYSA-N 4-[1-[(2-hydroxyphenyl)methyl]-5-(trifluoromethyl)imidazol-2-yl]benzonitrile Chemical compound OC1=C(CN2C(=NC=C2C(F)(F)F)C2=CC=C(C#N)C=C2)C=CC=C1 NPIUXDQKRHXKGZ-UHFFFAOYSA-N 0.000 description 2
• MOSRSUCLZNTQNP-UHFFFAOYSA-N 4-[1-[(2-methoxyphenyl)methyl]-5-(trifluoromethyl)imidazol-2-yl]benzonitrile Chemical compound COC1=C(CN2C(=NC=C2C(F)(F)F)C2=CC=C(C#N)C=C2)C=CC=C1 MOSRSUCLZNTQNP-UHFFFAOYSA-N 0.000 description 2
• SRKNTIQWWXWROR-UHFFFAOYSA-N 4-[1-[(2-methoxyphenyl)methyl]imidazol-2-yl]benzonitrile Chemical compound COC1=C(CN2C(=NC=C2)C2=CC=C(C#N)C=C2)C=CC=C1 SRKNTIQWWXWROR-UHFFFAOYSA-N 0.000 description 2
• WUVANLLLWYUAIU-UHFFFAOYSA-N 4-[5-iodo-1-[(2-methoxyphenyl)methyl]imidazol-2-yl]benzonitrile Chemical compound IC1=CN=C(N1CC1=C(C=CC=C1)OC)C1=CC=C(C#N)C=C1 WUVANLLLWYUAIU-UHFFFAOYSA-N 0.000 description 2
• VJQKWVRBYNWBNN-UHFFFAOYSA-N 4-chloro-N-(3,3,3-trifluoro-2,2-dihydroxypropyl)benzamide Chemical compound ClC1=CC=C(C(=O)NCC(C(F)(F)F)(O)O)C=C1 VJQKWVRBYNWBNN-UHFFFAOYSA-N 0.000 description 2
• PFRMFEOFGZHYMC-UHFFFAOYSA-N 4-fluoro-N-(3,3,3-trifluoro-2,2-dihydroxypropyl)benzamide Chemical compound FC1=CC=C(C(=O)NCC(C(F)(F)F)(O)O)C=C1 PFRMFEOFGZHYMC-UHFFFAOYSA-N 0.000 description 2
• YVAZHPIRCBOWLD-UHFFFAOYSA-N 4-iodo-N-(3,3,3-trifluoro-2,2-dihydroxypropyl)benzamide Chemical compound IC1=CC=C(C(=O)NCC(C(F)(F)F)(O)O)C=C1 YVAZHPIRCBOWLD-UHFFFAOYSA-N 0.000 description 2
• JTWFFPWWSKVUBO-UHFFFAOYSA-N 5-chloro-1-[(2-methoxyphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]imidazole Chemical compound ClC1=CN=C(N1CC1=C(C=CC=C1)OC)C1=CC=C(C=C1)C(F)(F)F JTWFFPWWSKVUBO-UHFFFAOYSA-N 0.000 description 2
• FEBCEHANEWRBDE-UHFFFAOYSA-N 6-[2-[[2-[4-(furan-2-yl)phenyl]-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]hexanoic acid Chemical compound O1C(=CC=C1)C1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCCCCC(=O)O)C=CC=C1 FEBCEHANEWRBDE-UHFFFAOYSA-N 0.000 description 2
• 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 2
• 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 2
• 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 206010012559 Developmental delay Diseases 0.000 description 2
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 102100039556 Galectin-4 Human genes 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
• 229910020667 PBr3 Inorganic materials 0.000 description 2
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 2
• BUZPORNLCIEDRH-YHMJZVADSA-N ethyl (3R)-5-(3,3-dimethyloxiran-2-yl)-3-methylpentanoate Chemical compound CC1(C(O1)CC[C@H](CC(=O)OCC)C)C BUZPORNLCIEDRH-YHMJZVADSA-N 0.000 description 2
• UAIOJGGMISJMMY-LLVKDONJSA-N ethyl (3r)-3,7-dimethyloct-6-enoate Chemical compound CCOC(=O)C[C@H](C)CCC=C(C)C UAIOJGGMISJMMY-LLVKDONJSA-N 0.000 description 2
• RTMVZAZNAONVCQ-MRVPVSSYSA-N ethyl (3r)-3-methyl-6-oxohexanoate Chemical compound CCOC(=O)C[C@H](C)CCC=O RTMVZAZNAONVCQ-MRVPVSSYSA-N 0.000 description 2
• MPAUPPXHWYAHSZ-UHFFFAOYSA-N ethyl 6-[2-[[2-(4-iodophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound IC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCCCCC(=O)OCC)C=CC=C1 MPAUPPXHWYAHSZ-UHFFFAOYSA-N 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 239000004026 insulin derivative Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• DMKJJRYYEGTEFE-UHFFFAOYSA-N methyl 2-[(4-chlorobenzoyl)amino]acetate Chemical compound COC(=O)CNC(=O)C1=CC=C(Cl)C=C1 DMKJJRYYEGTEFE-UHFFFAOYSA-N 0.000 description 2
• CUPZCSJVRWUUDJ-UHFFFAOYSA-N methyl 2-[(4-fluorobenzoyl)amino]acetate Chemical compound COC(=O)CNC(=O)C1=CC=C(F)C=C1 CUPZCSJVRWUUDJ-UHFFFAOYSA-N 0.000 description 2
• JBJFFQDDUCPNRU-UHFFFAOYSA-N methyl 2-[(4-iodobenzoyl)amino]acetate Chemical compound COC(=O)CNC(=O)C1=CC=C(I)C=C1 JBJFFQDDUCPNRU-UHFFFAOYSA-N 0.000 description 2
• LFYMSMABCXOUAV-UHFFFAOYSA-N methyl 2-[[4-(trifluoromethoxy)benzoyl]amino]acetate Chemical compound COC(=O)CNC(=O)C1=CC=C(OC(F)(F)F)C=C1 LFYMSMABCXOUAV-UHFFFAOYSA-N 0.000 description 2
• 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 2
• 230000004065 mitochondrial dysfunction Effects 0.000 description 2
• 102000006255 nuclear receptors Human genes 0.000 description 2
• 108020004017 nuclear receptors Proteins 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
• 238000010926 purge Methods 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
• VWYPNDAAFAAPKM-LJQANCHMSA-N (3R)-6-[2-[[2-[4-(furan-2-yl)phenyl]-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoic acid Chemical compound O1C(=CC=C1)C1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 VWYPNDAAFAAPKM-LJQANCHMSA-N 0.000 description 1
• KGQPMONVEZCVGM-QGZVFWFLSA-N (3R)-6-[2-[[5-cyano-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]-3-methylhexanoic acid Chemical compound C[C@H](CCCOc1ccccc1Cn1c(cnc1-c1ccc(cc1)C(F)(F)F)C#N)CC(O)=O KGQPMONVEZCVGM-QGZVFWFLSA-N 0.000 description 1
• FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
• VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
• QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
• RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
• BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
• LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
• DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• GPCJDSXBRMKASP-UHFFFAOYSA-N 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid Chemical compound OC(=O)C(Cl)(Cl)CCCCCCCCCCC1=CC=C(Cl)C=C1 GPCJDSXBRMKASP-UHFFFAOYSA-N 0.000 description 1
• LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
• NVWXSGQHHUSSOU-UHFFFAOYSA-N 2-[(4-fluorobenzoyl)amino]acetic acid Chemical compound OC(=O)CNC(=O)C1=CC=C(F)C=C1 NVWXSGQHHUSSOU-UHFFFAOYSA-N 0.000 description 1
• ZUGQWAYOWCBWGM-UHFFFAOYSA-N 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound CC=1N=C(C=2C(=CC(=CC=2)C(F)(F)F)F)SC=1CSC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ZUGQWAYOWCBWGM-UHFFFAOYSA-N 0.000 description 1
• QFYBRNTYTFDLHG-UHFFFAOYSA-N 2-[[4-(trifluoromethoxy)benzoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)C1=CC=C(OC(F)(F)F)C=C1 QFYBRNTYTFDLHG-UHFFFAOYSA-N 0.000 description 1
• RATSANVPHHXDCT-UHFFFAOYSA-N 4-(trifluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)(F)F)C=C1 RATSANVPHHXDCT-UHFFFAOYSA-N 0.000 description 1
• BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
• ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
• XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
• WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
• BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
• GHICCUXQJBDNRN-UHFFFAOYSA-N 4-iodobenzoic acid Chemical compound OC(=O)C1=CC=C(I)C=C1 GHICCUXQJBDNRN-UHFFFAOYSA-N 0.000 description 1
• 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• 208000028048 Accommodation disease Diseases 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 244000045410 Aegopodium podagraria Species 0.000 description 1
• RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
• 229920000856 Amylose Polymers 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
• CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
• QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
• 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
• 101000741797 Homo sapiens Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
• 206010021024 Hypolipidaemia Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 108010057186 Insulin Glargine Proteins 0.000 description 1
• COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
• 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
• ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
• PMPRXDUXGZPBFS-UHFFFAOYSA-N N-(3,3,3-trifluoro-2,2-dihydroxypropyl)-4-(trifluoromethoxy)benzamide Chemical compound FC(C(CNC(C1=CC=C(C=C1)OC(F)(F)F)=O)(O)O)(F)F PMPRXDUXGZPBFS-UHFFFAOYSA-N 0.000 description 1
• 102000034570 NR1 subfamily Human genes 0.000 description 1
• 108020001305 NR1 subfamily Proteins 0.000 description 1
• OKJHGOPITGTTIM-DEOSSOPVSA-N Naveglitazar Chemical compound C1=CC(C[C@H](OC)C(O)=O)=CC=C1OCCCOC(C=C1)=CC=C1OC1=CC=CC=C1 OKJHGOPITGTTIM-DEOSSOPVSA-N 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• JACYDSLPGULFSP-UHFFFAOYSA-N O.C(C)O.[Li] Chemical compound O.C(C)O.[Li] JACYDSLPGULFSP-UHFFFAOYSA-N 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 241000785681 Sander vitreus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 229940100389 Sulfonylurea Drugs 0.000 description 1
• 229940123464 Thiazolidinedione Drugs 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• 206010059790 Ulnar nerve palsy Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
• AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
• KOUAQOCYMAENKN-UHFFFAOYSA-N alpha-bromocaproic acid ethyl ester Natural products CCCCC(Br)C(=O)OCC KOUAQOCYMAENKN-UHFFFAOYSA-N 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
• 230000003178 anti-diabetic effect Effects 0.000 description 1
• 239000000883 anti-obesity agent Substances 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940125710 antiobesity agent Drugs 0.000 description 1
• VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
• RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
• 229940112930 apidra Drugs 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 125000005997 bromomethyl group Chemical group 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 229960003362 carbutamide Drugs 0.000 description 1
• VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 238000011072 cell harvest Methods 0.000 description 1
• 239000003610 charcoal Substances 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
• WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
• 229960002174 ciprofibrate Drugs 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 125000006003 dichloroethyl group Chemical group 0.000 description 1
• 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 125000006001 difluoroethyl group Chemical group 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
• 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
• 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 229910001651 emery Inorganic materials 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• HNPJNTRDGXQILF-GOSISDBHSA-N ethyl (3R)-6-[2-[[2-(4-bromophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound BrC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1 HNPJNTRDGXQILF-GOSISDBHSA-N 0.000 description 1
• GFZNTEYGNNNBQR-GOSISDBHSA-N ethyl (3R)-6-[2-[[2-(4-chlorophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1 GFZNTEYGNNNBQR-GOSISDBHSA-N 0.000 description 1
• YBIQJMRMALAVRR-LJQANCHMSA-N ethyl (3R)-6-[2-[[2-(4-cyanophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound C(#N)C1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1 YBIQJMRMALAVRR-LJQANCHMSA-N 0.000 description 1
• OIXDNVOYVZKLSM-GOSISDBHSA-N ethyl (3R)-6-[2-[[2-(4-fluorophenyl)-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound CCOC(=O)C[C@H](C)CCCOc1ccccc1Cn1c(cnc1-c1ccc(F)cc1)C(F)(F)F OIXDNVOYVZKLSM-GOSISDBHSA-N 0.000 description 1
• RLSAOKRISGWTMG-GOSISDBHSA-N ethyl (3R)-6-[2-[[5-chloro-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound ClC1=CN=C(N1CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1)C1=CC=C(C=C1)C(F)(F)F RLSAOKRISGWTMG-GOSISDBHSA-N 0.000 description 1
• HZZLFWJHJRWEDV-LJQANCHMSA-N ethyl (3R)-6-[2-[[5-cyano-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound C(#N)C1=CN=C(N1CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1)C1=CC=C(C=C1)C(F)(F)F HZZLFWJHJRWEDV-LJQANCHMSA-N 0.000 description 1
• STMFLZJRYPKCEH-UHFFFAOYSA-N ethyl 6-[2-[[2-[4-(furan-2-yl)phenyl]-5-(trifluoromethyl)imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound O1C(=CC=C1)C1=CC=C(C=C1)C=1N(C(=CN=1)C(F)(F)F)CC1=C(OCCCCCC(=O)OCC)C=CC=C1 STMFLZJRYPKCEH-UHFFFAOYSA-N 0.000 description 1
• KEQLCUZKLBSQTD-UHFFFAOYSA-N ethyl 6-bromo-3-methylhexanoate Chemical compound CCOC(=O)CC(C)CCCBr KEQLCUZKLBSQTD-UHFFFAOYSA-N 0.000 description 1
• DXBULVYHTICWKT-UHFFFAOYSA-N ethyl 6-bromohexanoate Chemical compound CCOC(=O)CCCCCBr DXBULVYHTICWKT-UHFFFAOYSA-N 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
• 229950003707 farglitazar Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• 229960001419 fenoprofen Drugs 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960004580 glibenclamide Drugs 0.000 description 1
• 229960001764 glibornuride Drugs 0.000 description 1
• RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
• 229960000346 gliclazide Drugs 0.000 description 1
• 229960004346 glimepiride Drugs 0.000 description 1
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
• 229960001381 glipizide Drugs 0.000 description 1
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
• 229960003468 gliquidone Drugs 0.000 description 1
• 229950008402 glisentide Drugs 0.000 description 1
• NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 description 1
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
• 229950000958 halofenate Drugs 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• NUKZAGXMHTUAFE-UHFFFAOYSA-N hexanoic acid methyl ester Natural products CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 1
• 201000001451 hypomyelinating leukodystrophy Diseases 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
• 108700039926 insulin glulisine Proteins 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940060975 lantus Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
• 229950009116 mevastatin Drugs 0.000 description 1
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 229950001135 muraglitazar Drugs 0.000 description 1
• 230000009756 muscle regeneration Effects 0.000 description 1
• 210000003098 myoblast Anatomy 0.000 description 1
• 230000003274 myotonic effect Effects 0.000 description 1
• REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
• QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229950003494 naveglitazar Drugs 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
• 229950001628 netoglitazone Drugs 0.000 description 1
• 208000008795 neuromyelitis optica Diseases 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000006611 pharmacological activation Effects 0.000 description 1
• 229960005222 phenazone Drugs 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
• 229950010764 rivoglitazone Drugs 0.000 description 1
• 229960004586 rosiglitazone Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229960002277 tolazamide Drugs 0.000 description 1
• OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 208000036722 ulnar neuropathy Diseases 0.000 description 1
• 125000005500 uronium group Chemical group 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1